| 发布于: | Android | 转发：0 | 回复：3 | 喜欢：1 |
$和黄医药(00013)$ 武田的电话会议关于Fruzaqla的部分
“Fruzaqla, which we acquired through an exclusive license agreement with HUTCHMED in March last year, it is the first and only targeted therapy approved for metastatic colorectal cancer regardless of biomarker status in ...
分成15%以上。确实这样，我现在觉得和黄医药应该大幅搞双抗或者ADC，放开搞，不要收缩管线。